BMY
Two years in, still standing
Bristol Myers Squibb is back with more Sotyktu chatter, this time showing durable efficacy and consistent safety over two years in adults with psoriatic arthritis. In drug-world terms, that’s the equivalent of a sequel not totally ruining the original.
Why investors should care
When a therapy can keep doing its job over the long haul without new safety drama, it gets a lot easier to build a real commercial story around it. For BMS, that matters because Sotyktu isn’t just a science project — it’s one of the assets that can help support growth in an increasingly crowded immunology aisle.
The readout in plain English
- The efficacy held up over two years, which is what you want if you’re trying to convince doctors the drug works beyond the honeymoon phase.
- Safety stayed consistent, which is especially important for chronic conditions where patients may be on therapy for a long time.
- The data adds another brick to BMS’s case that Sotyktu can be more than a one-hit wonder.
Big picture: investors don’t just buy molecules, they buy staying power. And this update is basically BMS saying Sotyktu can stick around.